Does Red Yeast Rice Cause Muscle Pain?

Red yeast rice can cause muscle pain, and the reason is straightforward: its active ingredient, monacolin K, is chemically identical to the prescription statin drug lovastatin. That means it carries many of the same side effects, including the muscle soreness and weakness that statins are known for. But the picture is more nuanced than a simple yes. In clinical trials, people taking red yeast rice reported muscle symptoms at rates similar to those taking a placebo, and the real dangers tend to cluster around dose uncertainty, drug interactions, and individual susceptibility rather than the supplement itself being inherently risky at moderate doses.

Why Red Yeast Rice Acts Like a Statin

Red yeast rice is made by fermenting white rice with a fungus called Monascus purpureus (or related species). During fermentation, the fungus produces a family of compounds called monacolins, the most important of which is monacolin K. This compound is not just “similar to” lovastatin; it is lovastatin, down to the molecular structure.¹ That means when you swallow a red yeast rice capsule, your body processes it the same way it would process a prescription statin. It inhibits the same enzyme in the liver that controls cholesterol production, and it exposes your muscles to the same biochemical stress.

Statin-associated muscle symptoms range from mild achiness and stiffness to outright weakness. The mechanism isn’t fully settled even for prescription statins, but the leading theory involves reduced production of coenzyme Q10 and disrupted energy metabolism in muscle cells. Because monacolin K works through the same pathway, red yeast rice can trigger the same cascade. The question isn’t really whether it can cause muscle pain; it’s how often it does and how serious the pain gets.

What the Clinical Trials Show

If you look only at case reports and warning labels, red yeast rice sounds alarming. But when researchers run controlled trials where some participants get red yeast rice and others get a placebo, the results are surprisingly reassuring. A meta-analysis pooling 20 randomized trials with over 6,600 patients found that muscle symptom rates ranged from zero to about 24% in the red yeast rice groups, but from zero to 36% in the placebo groups.² In other words, people who thought they might be taking a cholesterol supplement reported just as much muscle discomfort whether or not the capsule contained any active ingredient.

That pattern echoes what researchers see with prescription statins, where a large proportion of reported muscle pain appears to be driven by expectation rather than pharmacology. The same meta-analysis found no evidence of increased risk for musculoskeletal problems even when the data was broken down by monacolin K dose, and no cases of rhabdomyolysis or dangerously elevated muscle enzymes appeared in any of the included studies.² Across real-world adverse event databases, musculoskeletal disorders linked to red yeast rice accounted for just 0.002% of all reported musculoskeletal cases.²

This doesn’t mean muscle pain from red yeast rice is imaginary. Some people clearly do experience real, pharmacologically driven symptoms. But the trial evidence suggests the base rate is lower than what gets reported in everyday use, where anxiety about side effects amplifies the signal.

How Red Yeast Rice Compares to Prescription Statins

One of the main selling points of red yeast rice is the idea that it’s “gentler” than a prescription statin. There’s some clinical support for that framing, though it comes with caveats. In a small trial of patients who had already quit prescription statins because of muscle problems, red yeast rice and pravastatin were tolerated equally well. About 5% of the red yeast rice group and 9% of the pravastatin group dropped out due to muscle pain, a difference that wasn’t statistically meaningful.³ Both groups achieved similar cholesterol reductions.

A separate pilot trial compared red yeast rice to simvastatin, a more potent statin. At the end of the study period, patients on simvastatin reported significantly more fatigue and reduced physical activity, while the red yeast rice group showed no meaningful change in those measures.⁴ Both groups had similar lipid-lowering effects. These are small studies, so they’re not definitive, but they do suggest that at the doses typically used, red yeast rice may produce fewer subjective muscle complaints than some prescription statins while delivering comparable cholesterol benefits.

The likely explanation is dose. A typical red yeast rice supplement delivers somewhere between 3 and 10 milligrams of monacolin K per day, which is on the low end of what a prescription lovastatin dose would be. Lower drug exposure tends to mean fewer side effects. Red yeast rice also contains other fermentation byproducts, including plant sterols and unsaturated fatty acids, which may contribute to its cholesterol-lowering effect without adding to the muscle risk.

When Muscle Pain Turns Dangerous

The worst-case scenario with any statin, including monacolin K, is rhabdomyolysis: a rapid breakdown of muscle tissue that floods the bloodstream with proteins and can lead to kidney failure. It’s rare, but it has happened with red yeast rice. A published case involved a 76-year-old man who developed progressive limb weakness, muscle soreness, and acute kidney injury after adding a red yeast rice supplement to his existing medications, which included the cancer drug abiraterone. He required hemodialysis and nearly a month of treatment before his muscle enzymes returned to normal.⁵

In another case, a 50-year-old woman with no other obvious risk factors presented with sudden chest discomfort and widespread muscle pain; lab work confirmed rhabdomyolysis linked to her red yeast rice use.⁶ These cases are exceptional, and none of the randomized trials have ever produced a rhabdomyolysis event. But they underscore an important point: the fact that red yeast rice is sold as a supplement does not make it incapable of causing the same serious harm as a prescription statin.

Analysis of adverse event databases reinforces that while serious events are uncommon, they’re real. In the U.S. FDA’s reporting system, rhabdomyolysis and myopathy cases linked to red yeast rice showed up at rates significantly higher than what you’d expect by chance, with a reporting odds ratio above eight for serious muscle injuries.⁷ Adverse event databases have well-known limitations: they capture voluntary reports, not controlled measurements, and they can’t establish that the supplement definitively caused the problem. But the signal is consistent enough that regulators have taken notice.

The Supplement Quality Problem

One of the biggest practical risks with red yeast rice has nothing to do with the supplement’s pharmacology and everything to do with what’s actually in the bottle. Unlike prescription lovastatin, which is manufactured to precise dosing standards, red yeast rice supplements vary wildly in their monacolin K content. A study of 28 commercial brands found that the amount of monacolin K per capsule ranged from 0.10 to 10.09 milligrams, a roughly 100-fold spread.⁸

A later analysis of 26 brands from mainstream U.S. retailers found the situation hadn’t improved. Monacolin K content ranged more than 60-fold per capsule, and when you followed each brand’s recommended daily serving, the actual daily intake ranged more than 120-fold, from 0.09 to nearly 11 milligrams.⁹ Some products delivered a pharmacologically trivial dose. Others delivered a dose equivalent to a moderate prescription statin. A consumer switching brands, or even switching lots within the same brand, could unknowingly double or halve their drug exposure.

This variability matters because dose determines risk. A capsule with 0.5 milligrams of monacolin K is unlikely to cause muscle symptoms in anyone. A capsule with 10 milligrams delivers a genuine statin dose and carries genuine statin risks, especially if you’re also taking other medications that interact with lovastatin. The person most likely to get into trouble is someone who assumes all red yeast rice supplements are interchangeable and accidentally steps into a high-dose product without realizing it.

Drug Interactions That Amplify the Risk

Because monacolin K is lovastatin, it’s subject to the same drug interactions that lovastatin is. The most clinically important ones involve drugs that slow down the liver enzymes responsible for breaking lovastatin down. When those enzymes are inhibited, lovastatin accumulates in the bloodstream at higher-than-expected concentrations, and muscle toxicity risk climbs. Common offenders include certain antifungal drugs, some antibiotics, grapefruit juice in large quantities, and other cholesterol-lowering agents.

One study specifically tested what happens when red yeast rice is combined with gemfibrozil, a fibrate drug sometimes used alongside statins for lipid management. The combination significantly increased blood levels of lovastatin acid, the active form of the drug.¹⁰ That finding has direct relevance for muscle safety: higher circulating lovastatin means more drug reaching muscle cells, and more opportunity for damage. Both rhabdomyolysis case reports discussed earlier involved patients on other medications that could have interacted with monacolin K.

The practical issue is that many people turn to red yeast rice precisely because they want to manage cholesterol “naturally” and may not mention it to their doctor. If you’re already on a medication that interacts with statins, adding red yeast rice is adding a statin without your physician’s knowledge. That blind spot is where the most serious adverse events tend to happen.

Citrinin Contamination

Monacolin K isn’t the only biologically active compound that can show up in red yeast rice. The fermentation process can also produce citrinin, a mycotoxin with potential to damage the kidneys and liver.¹¹ Whether citrinin actually appears in a given product depends on which fungal strain is used. Research has shown that the species Monascus purpureus can produce citrinin but may not produce much monacolin K, while Monascus ruber tends to produce monacolin K without citrinin.¹² In practice, this means the toxicity profile of a red yeast rice supplement depends not only on how much monacolin K it contains but also on the manufacturing process and the fungal species involved.

Testing of supplements on the European market has generally been reassuring: one study of commercially available red yeast rice products found none with citrinin above the limit of detection.¹¹ But the European Union has set a legal maximum for citrinin in food supplements, which has pushed reputable manufacturers to control for it. In markets with less regulatory oversight, the risk may be higher. Citrinin wouldn’t cause the classic muscle soreness associated with statins, but it could contribute to kidney or liver symptoms that get mistakenly lumped in with “red yeast rice side effects.”

What European Regulators Have Decided

The European Food Safety Authority has issued two major opinions on monacolin K from red yeast rice, and the conclusions are notably cautious. In 2018, EFSA’s expert panel concluded that monacolins from red yeast rice “at the use level of 10 mg/day” were a significant safety concern and that individual cases of severe adverse reactions had been reported at intakes as low as 3 milligrams per day.¹³ Severe effects included rhabdomyolysis and liver damage.

In 2025, EFSA revisited the question after receiving new data from industry and health agencies across Europe. The panel reiterated its earlier concerns, stating that monacolin K from red yeast rice at intakes as low as 3 milligrams per day could lead to severe musculoskeletal effects. It went further, concluding that the data submitted did not allow establishing the safety of monacolins even below 3 milligrams per day, and that no daily intake level could be identified that “does not raise safety concerns for the general population or vulnerable subgroups.”¹⁴

That’s a striking position. EFSA is essentially saying it can’t identify any dose of monacolin K in a supplement that it’s confident is safe for everyone. Several EU member states have already imposed restrictions on monacolin K content in supplements, with some capping it at 3 milligrams and others effectively banning it. The U.S. FDA takes a different approach: it has warned companies against marketing red yeast rice products that contain more than trace amounts of monacolin K, on the grounds that lovastatin is an approved drug and selling it as a supplement is illegal. In practice, though, products with pharmacologically active doses remain widely available on American store shelves.

Who Is Most Vulnerable

Certain groups face higher risk of muscle problems from red yeast rice, for the same reasons they face higher risk from prescription statins. Older adults tend to metabolize drugs more slowly, meaning a given dose of monacolin K lingers in the body longer and reaches higher concentrations. People with kidney impairment are at increased risk because one of the ways the body clears lovastatin is through the kidneys. Hypothyroidism, which is common in older women, independently raises the risk of muscle complaints from statins and likely does the same for monacolin K.

People taking multiple medications are another high-risk group, as described in the drug interaction section above. And people who are already statin-intolerant should be aware that switching to red yeast rice isn’t the same as switching to a different drug class. You’re still taking a statin; it just comes in a different package. Some statin-intolerant patients do tolerate red yeast rice well, possibly because the dose is lower or because other compounds in the fermented rice modulate the effect. But going in expecting zero risk is a mistake.

Coenzyme Q10 and Other Protective Strategies

You’ll often see red yeast rice marketed alongside coenzyme Q10 (CoQ10), with the implication that CoQ10 prevents the muscle pain that statins can cause. The logic is reasonable on paper: statins reduce the body’s production of CoQ10 along with cholesterol, and some researchers have theorized that supplementing CoQ10 could protect muscles. But the evidence specifically testing whether CoQ10 prevents muscle issues from red yeast rice is thin. Most of the CoQ10 research has been done on prescription statins, and even there the results are mixed, with some trials showing modest benefit and others showing none.

If you’re experiencing muscle pain while taking red yeast rice, the most straightforward move is to stop taking it and see if the pain resolves within a few weeks. If it does, the supplement was likely the cause. If muscle pain is accompanied by dark-colored urine, significant weakness, or swelling, those are signs of possible rhabdomyolysis and warrant immediate medical attention. Switching to a different brand of red yeast rice won’t necessarily help if the issue is monacolin K itself, but it could matter if the issue was an unusually high-dose product. Given the extreme variability between brands, a product switch can mean a dramatic change in actual drug exposure without the consumer realizing it.

For people who want the cholesterol benefits and want to minimize muscle risk, the evidence points toward using products with clearly labeled, standardized monacolin K content at the low end of the dosing range, avoiding concurrent use of drugs known to interact with lovastatin, and treating the supplement as what it biochemically is: a medication that deserves the same informed decision-making as a prescription.